Clinical Trial Update: Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating adaptive immunotherapy with a VEGFR-TKI in patients with advanced renal cell carcinoma has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma | Phase 2 | Status: SUSPENDED